The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2020

Filed:

Jul. 18, 2017
Applicant:

Mor-nuco Enterprises, Inc., West Lafayette, IN (US);

Inventors:

D. James Morre, West Lafayette, IN (US);

Brandon Eugene Hostetler, West Lafayette, IN (US);

James Jinpal Kim, West Lafayette, IN (US);

Assignee:

Mor-NuCo Enterprises, Inc., West Lafayette, IN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/00 (2006.01); G01N 33/574 (2006.01); C07K 16/18 (2006.01); C07K 16/40 (2006.01); C07K 14/79 (2006.01); C07K 14/81 (2006.01); C12N 9/02 (2006.01); C12N 9/16 (2006.01); C12N 9/96 (2006.01); G01N 27/447 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); C07K 14/79 (2013.01); C07K 14/8125 (2013.01); C07K 16/18 (2013.01); C07K 16/40 (2013.01); C12N 9/0036 (2013.01); C12N 9/16 (2013.01); C12N 9/96 (2013.01); C12Y 106/00 (2013.01); C12Y 301/03001 (2013.01); G01N 27/4473 (2013.01); G01N 27/44726 (2013.01); G01N 27/44747 (2013.01); G01N 27/44795 (2013.01); G01N 33/57419 (2013.01); G01N 33/57423 (2013.01); G01N 33/57488 (2013.01); C07K 2317/622 (2013.01); C07K 2319/61 (2013.01); G01N 2333/705 (2013.01); G01N 2333/902 (2013.01); G01N 2333/90209 (2013.01); G01N 2333/916 (2013.01);
Abstract

Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.


Find Patent Forward Citations

Loading…